Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.
about
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerCross talk of tyrosine kinases with the DNA damage signaling pathwaysTargeting DNA damage response in cancer therapyMicrohomology-Mediated End Joining: A Back-up Survival Mechanism or Dedicated Pathway?c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated LeukemiasInter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair researchDeregulation of DNA double-strand break repair in multiple myeloma: implications for genome stabilityEnhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for CancerTaking a Bad Turn: Compromised DNA Damage Response in LeukemiaStructure and function of the DNA ligases encoded by the mammalian LIG3 gene.DNA ligases as therapeutic targetsIdentifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line.Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid LeukemiaHuman DNA ligase III bridges two DNA ends to promote specific intermolecular DNA end joiningUV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib.Processing by MRE11 is involved in the sensitivity of subtelomeric regions to DNA double-strand breaks.DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitorsRisky business: Microhomology-mediated end joining.Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IVPARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.While at Rome miRNA and TRAIL do whatever BCR-ABL commands to do.Human DNA ligases: a comprehensive new look for cancer therapy.hPso4/hPrp19: a critical component of DNA repair and DNA damage checkpoint complexes.Inhibiting Mitochondrial DNA Ligase IIIα Activates Caspase 1-Dependent Apoptosis in Cancer CellsA comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative NeoplasmsGenomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.Structure-activity relationships among DNA ligase inhibitors: Characterization of a selective uncompetitive DNA ligase I inhibitor.Kinetic analyses of single-stranded break repair by human DNA ligase III isoforms reveal biochemical differences from DNA ligase I.Repair of DNA double-strand breaks by mammalian alternative end-joining pathways.
P2860
Q26776513-EDE6C6CE-6426-4A69-BE56-9EAA95075E91Q26778614-F3D31FC8-D8B4-41DB-A3FE-1C27A8B37989Q27023204-30CA0CDE-5143-4359-8655-68EB4FE0D542Q28083182-32392D28-7158-4402-A7F7-82D0E8D2D6A3Q28259732-9A235DD8-499F-4AC6-A31C-73AD42BF5DD5Q28388726-382F70AC-431D-44E3-8425-818AA36B075FQ28544696-14C138D4-9D8B-4B05-833B-EAEB3DC48063Q29147555-35A363FE-2417-44D3-9005-212134776FB2Q33855938-6011D485-57A7-4585-BBD9-E63CA1284568Q34369324-3364AF97-987B-444F-B63F-040BDD894F36Q34384677-546F49BC-B4C9-4AB2-A507-BE5F0BEB8BD1Q34703835-80E080F1-F544-4AC0-8D28-BCDF831567EBQ34781322-6EECD2D5-08A3-47F0-96F0-B0B8C297AFA0Q35961937-C8918E9B-D229-432F-8872-A6AEBA3AF32CQ36088545-9C537A71-E1EC-4266-AD01-04BAD1217FDBQ36299151-6104D142-25C9-4427-A791-E656FCE75768Q36413681-4C0C12F9-C428-40A6-9D87-171CBF7EEA65Q36946591-CC9299B0-8196-4FAC-A484-82BBA3530519Q36952240-74E0900D-48C5-4E54-B74D-FF6B2C9CA90CQ37223734-59605A4B-FD50-4AAE-9C03-B870FE8DE3E9Q37296869-F5785AD1-0F0E-4BE8-9358-DE07AFC23844Q37688982-3BC1C87E-6E5C-4801-AFC2-1A0EFC211507Q38066406-C6AFF78D-6115-49B2-837D-7FF7BE03ED14Q38130159-3E9747AC-DF8A-4509-9530-3B0F89787F41Q38585845-B92A48E7-2C9D-4086-8E48-BB66FAB0AE18Q38752920-C3660E15-07A9-4054-B814-171305AD2D9BQ38780396-202F0144-2A74-4B87-A893-3BCA98C69D37Q41217822-F1889C33-4129-4B40-B26F-9202DCC90A5CQ46406409-868E8B72-EAA1-4422-B8D5-EEDFB5E22BC6Q47151745-2B5B0521-9E55-4102-B1A9-6629418210A8Q47296065-30A28837-E237-4F7A-BCBE-EE4933F27760Q47872719-96E38309-0FF6-4508-8C67-F0CBC06ADA53Q48019352-15BB15BC-0EE0-4809-97EB-1F0CF475EBCAQ52659674-A347DA99-ACF6-461A-B392-6D87529BD613
P2860
Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Targeting abnormal DNA double- ...... ant chronic myeloid leukemias.
@ast
Targeting abnormal DNA double- ...... ant chronic myeloid leukemias.
@en
Targeting abnormal DNA double- ...... ant chronic myeloid leukemias.
@nl
type
label
Targeting abnormal DNA double- ...... ant chronic myeloid leukemias.
@ast
Targeting abnormal DNA double- ...... ant chronic myeloid leukemias.
@en
Targeting abnormal DNA double- ...... ant chronic myeloid leukemias.
@nl
prefLabel
Targeting abnormal DNA double- ...... ant chronic myeloid leukemias.
@ast
Targeting abnormal DNA double- ...... ant chronic myeloid leukemias.
@en
Targeting abnormal DNA double- ...... ant chronic myeloid leukemias.
@nl
P2093
P2860
P356
P1433
P1476
Targeting abnormal DNA double- ...... ant chronic myeloid leukemias.
@en
P2093
A E Tomkinson
A P Rapoport
F V Rassool
P2860
P2888
P304
P356
10.1038/ONC.2012.203
P407
P577
2012-05-28T00:00:00Z
P5875
P6179
1035408028